Considering that the PD-1/PD-L1 axis is effective in triple-negative invasive breast cancer immunotherapy [19], the prognostic and therapeutic value of PD-L1 in DCIS remains to be further investigated. The gene discussed is CD274; the disease is ductal breast carcinoma in situ.